Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.50 |
| ▸ | GCGR | P47871 | 6/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | FRK | P42685 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099737 | 0.85 | GCGR (0.47) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL8987430 | 0.76 | KDM4E (0.41) | MAP4K4ADORA2AADORA1ALOX5KDM4E | |
| SCHEMBL8987328 | 0.75 | PARP1 (0.48) | KDM4EALDH1A1CYP1A2MAPTCYP2C9 | |
| SCHEMBL4672512 | 0.75 | MAPK14 (0.53) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL1554633 | 0.74 | MAPK14 (0.53) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL6077530 | 0.74 | MAPK14 (0.53) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL1554763 | 0.73 | MAPK14 (0.51) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL8987013 | 0.72 | PDGFRB (0.49) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL20675707 | 0.72 | ADORA2A (0.51) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL5850335 | 0.71 | MAPK14 (0.65) | MAPK14GCGRMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | MAPK14 2062/4885GCGR 2080/4885MAPK13 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.